Menu Search
Equities

Medios AG

ILM1X:GER

Medios AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)13.02
  • Today's Change-0.14 / -1.06%
  • Shares traded22.81k
  • 1 Year change-25.17%
  • Beta0.9814
Data delayed at least 15 minutes, as of Nov 22 2024 14:20 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Medios AG had little change in net income (from 18.33m to 18.81m) despite revenues that grew 10.80% from 1.61bn to 1.78bn. A contributing factor has been an increase in the cost of goods sold as a percent of sales from 93.37% to 93.86%.
Gross margin7.19%
Net profit margin0.70%
Operating margin1.52%
Return on assets1.67%
Return on equity2.65%
Return on investment2.36%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Medios AG fell by 8.17m. However, the company earned 16.41m from its operations for a Cash Flow Margin of 0.92%. In addition the company used 16.57m on investing activities and also paid 8.01m in financing cash flows.
Cash flow per share1.65
Price/Cash flow per share8.42
Book value per share19.90
Tangible book value per share-0.2439
More ▼

Balance sheet in EURView more

Medios AG has a Debt to Total Capital ratio of 31.74%, a higher figure than the previous year's 3.11%.
Current ratio0.9885
Quick ratio0.7551
Total debt/total equity0.4649
Total debt/total capital0.3174
More ▼

Growth rates in EUR

Year on year, growth in earnings per share excluding extraordinary items increased 2.44%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)20.26
EPS (TTM) vs
TTM 1 year ago		-32.83
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.